Catch up on the top radiology content of the past week.
|Articles|August 19, 1998
Life Imaging offers ultrasound 3-D
Three-dimensional ultrasound developer Life Imaging Systems of London, Ontario, has begun offering a 3-D visualization software developer's kit to medical imaging OEMs. The Windows NT-based kit is part of Life's L3D family of products and allows OEMs to
Advertisement
Three-dimensional ultrasound developer Life Imaging Systems of London, Ontario, has begun offering a 3-D visualization software developer's kit to medical imaging OEMs. The Windows NT-based kit is part of Life's L3D family of products and allows OEMs to add 3-D ultrasound visualization to their 2-D systems.
Advertisement
Related to this article
Assessing breast MRI scans, pathology and clinical data, the AI-powered TumorSight Risk software reportedly provides five- and 10-year risk for breast cancer recurrence for women with HR+, HER2-negative stage I-IIIA breast cancer.
While a new article raises provocative questions about the capability of photon-counting CT (PCCT) to perhaps replace diagnostic ICA, the real revolution with this modality is going beyond stenosis measurement to a renewed focus on the disease of atherosclerosis.
Catch up on the latest imaging research presented at the recent American Society for Radiation Oncology (ASTRO) Annual Meeting.
Tightness of the high-convexity sulci (THC) on brain MRI was associated with nearly threefold higher odds of cognitive decline over five to seven years of follow-up, according to a new prospective study involving over 2,100 community-dwelling senior citizens.
An AI model for prostate MRI offered an 89 percent AUC for prostate cancer detection in external validation testing, according to a newly published international multicenter study.
In the latest episode of her Breast Imaging in Focus series, Manisha Bahl, MD, MPH, FSBI, discusses new research comparing mammography-based AI models for breast cancer detection and short-term risk prediction.
In a recent episode of our Molecular Imaging in Focus series, Jack Andrews, MD, discussed pertinent findings from a recent intra-patient comparative study of PSMA PET agents in men with recurrent prostate cancer presented at the recent ASTRO conference.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
What a Large Prostate MRI Study Reveals About AI and Unassisted Radiologist Assessment
2
FDA Clears First MRI-Derived AI Software for Assessing Breast Cancer Recurrence Risk
3
How Photon-Counting CT Helps Us Recognize that Coronary Stenosis is Just One Piece of the Puzzle
4
Breast Imaging in Focus: Can AI Models for Breast Cancer Detection and Risk Prediction Be Used Interchangeably?
5